207 results on '"Eleveld, Douglas J."'
Search Results
2. Neuromuscular end-point predictive capability of published rocuronium pharmacokinetic/pharmacodynamic models: An observational trial
3. Pharmacodynamic mechanism-based interaction model for the haemodynamic effects of remifentanil and propofol in healthy volunteers
4. General purpose models for intravenous anesthetics, the next generation for target-controlled infusion and total intravenous anesthesia?
5. Bayesian statistics in anesthesia practice: a tutorial for anesthesiologists
6. Mechanism-based pharmacodynamic model for propofol haemodynamic effects in healthy volunteers☆
7. Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia
8. Target-controlled-infusion models for remifentanil dosing consistent with approved recommendations
9. Target controlled infusion of remimazolam in healthy volunteers shows some acute tolerance
10. Meta-analysis of Ketamine Pharmacokinetics: Lots of Work Done but Still Lots to Do
11. Immobility
12. Propofol PK-PD
13. Population Pharmacodynamic Modeling Using the Sigmoid Emax Model: Influence of Inter-individual Variability on the Steepness of the Concentration–Effect Relationship. a Simulation Study
14. Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations
15. Do Vancomycin Pharmacokinetics Differ Between Obese and Non-obese Patients? Comparison of a General-Purpose and Four Obesity-Specific Pharmacokinetic Models
16. Modeling the Effect of Excitation on Depth of Anesthesia Monitoring in γ-Aminobutyric Acid Type A Receptor Agonist ABP-700
17. Propofol Breath Monitoring as a Potential Tool to Improve the Prediction of Intraoperative Plasma Concentrations
18. Allometric Scaling in Pharmacokinetic Studies in Anesthesiology.
19. Clinical validation of pharmacokinetic/pharmacodynamic models for propofol infusion. Response to Br J Anaesth 2021: 126: e172-4
20. Comment on Morse et al. A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. J. Clin. Med. 2020, 9, 3480
21. Does it matter how you get from D (drug dose) to E (clinical effect)?
22. Haemodialysis followed by continuous veno-venous haemodiafiltration in lithium intoxication; a model and a case
23. Moxifloxacin dosing in post-bariatric surgery patients
24. Mechanism-based pharmacodynamic model for propofol haemodynamic effects in healthy volunteers☆.
25. Resisting neural inertia: an exercise in floccinaucinihilipilification?
26. Population Pharmacodynamic Modeling Using the Sigmoid Emax Model: Influence of Inter-individual Variability on the Steepness of the Concentration–Effect Relationship. a Simulation Study
27. Twitch Potentiation Influences the Time Course of Twitch Depression in Muscle Relaxant Studies: A Pharmacokinetic-Pharmacodynamic Explanation
28. Performance of an Iterative Two-Stage Bayesian Technique for Population Pharmacokinetic Analysis of Rich Data Sets
29. Improving Pharmacokinetic–Pharmacodynamic Models of Muscle Relaxants Using Potentiation Modelling
30. Do Vancomycin Pharmacokinetics Differ Between Obese and Non-obese Patients? Comparison of a General-Purpose and Four Obesity-Specific Pharmacokinetic Models
31. Modeling the Effect of Excitation on Depth of Anesthesia Monitoring in γ-Aminobutyric Acid Type A Receptor Agonist ABP-700
32. A Pharmacokinetic–Pharmacodynamic Model for Neuromuscular Blocking Agents to Predict Train-of-Four Twitches
33. Obesity and Allometric Scaling of Pharmacokinetics
34. A hitch-hikerʼs guide to the intravenous PK/PD galaxy
35. Genetic Algorithms as a Tool for Dosing Guideline Optimization: Application to Intermittent Infusion Dosing for Vancomycin in Adults
36. Population pharmacokinetics and pharmacodynamics in anesthesia, intensive care and pain medicine
37. Simultaneous versus Sequential Pharmacokinetic-pharmacodynamic Population Analysis using an Iterative Two-Stage Bayesian Technique
38. Parametric and Nonparametric Population Methods
39. Target‐controlled‐infusion for special populations: How different is different enough?
40. Performance of an Iterative Two-stage Bayesian Technique for Population Pharmacokinetic Analysis of Rich Data Sets
41. A Phase 1, Single-center, Double-blind, Placebo-controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Clinical Effects, and Pharmacokinetics–Pharmacodynamics of Intravenous Cyclopropyl-methoxycarbonylmetomidate (ABP-700) after a Single Ascending Bolus Dose
42. An Allometric Model of Remifentanil Pharmacokinetics and Pharmacodynamics
43. A New Pharmacokinetic Model of Propofol: Effect of Age on Clearance and Impact of the Terminal Distribution Phase Response
44. A response surface model approach for continuous measures of hypnotic and analgesic effect during sevoflurane-remifentanil interaction: quantifying the pharmacodynamic shift evoked by stimulation
45. What about confidence intervals? A word of caution when interpreting PTA simulations
46. Performance of the Eleveld pharmacokinetic model to titrate propofol in an obese Japanese patient population
47. Propofol Breath Monitoring as a Potential Tool to Improve the Prediction of Intraoperative Plasma Concentrations
48. Influence of the method of PK and PD modeling on the objective function and the PD parameters
49. Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers
50. In Response
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.